<DOC>
	<DOCNO>NCT00896558</DOCNO>
	<brief_summary>This study first repeat dose administration GSK1322322 investigate safety , tolerability , pharmacokinetics healthy subject well elderly volunteer subject . The study also include P450 probe drug ( midazolam ) evaluate effect GSK1322322 inhibit induce CYP3A4 substrates .</brief_summary>
	<brief_title>A Repeat Dose Escalation Study Investigate Safety , Tolerability Pharmacokinetics GSK1322322 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>The subject healthy . Male female 18 65 year age inclusive , time signing inform consent ( except elderly cohortPart B , see # 8 ) .. A female eligible enter participate study nonchildbearing potential Male subject must agree use one contraception method protocol Body weight great equal 50 kg body mass index 18.529.9 kg/m2 inclusive Capable give write informed consent QTcB le 450 msec ; QTc le 480 msec subject Bundle Branch Block Screening ECG Part B/Cohort E Elderly cohort : The subject great 65 year age . The subject positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define protocol The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive human chorionic gonadotropin test screen prior dosing . Lactating female . Subjects asthma history asthma within past 6 month . History smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice , pummelo , satsuma , ugli , tangerine , tangelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . For probe cohort Part A : condition symptom contraindicate administration midazolam include acute narrowangle openangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK1322322 , repeat dose , healthy subject , elderly , drug-drug interaction , probe , midazolam , double-blind</keyword>
</DOC>